PVM Researcher Helps Lead Purdue Effort to Take ‘Accelerator’ off Aggressive Prostate and Other Deadly Tumors

Purdue Veterinary Medicine Associate Professor of Basic Medical Sciences Marxa Figueiredo helped lead a Purdue research team studying ways to make prostate cancer less lethal by making it less aggressive. Prostate cancer is ranked as the second most common and second most fatal cancer among men by the American Cancer Society.

Dr. Figueiredo pictured with student in lab

Purdue University associate professor Marxa Figueiredo, right, worked with students as she helped lead a team developing an anti-cancer drug with potential to help people and animals.

The Purdue team has developed a drug to target the laminin receptor (37/67 LR), a membrane protein that, when overexpressed, can promote the growth of cancer cells and tumors. The researchers say it also could help fight other types of aggressive cancers, including pancreatic, colon, liver, and breast.

“We are trying to take cancer’s foot off the accelerator by targeting this receptor,” said Dr. Figueiredo. Purdue’s drug binds to the laminin receptor and cuts its ability to help tumors grow and to communicate with blood vessels, which are the lifeblood for cancer cells and tumors. The Purdue compound mimics anti-proliferative and anti-angiogenesis pathways to inhibit cancer cell viability, proliferation, and migration as well the formation of new blood vessels.

new compound pictured

This image shows two poses for a new compound, discovered at Purdue University, docking and targeting the laminin receptor protein for cancer therapy.

The work also aligns with Purdue’s Giant Leaps celebration, acknowledging the University’s global advancements made in health, longevity, and quality of life as part of Purdue’s 150th anniversary. This is one of the four themes of the yearlong celebration’s Ideas Festival, designed to showcase Purdue as an intellectual center solving real-world issues. Solutions such as this drug are also a focus of Purdue’s Discovery Park District.

The Purdue approach is unique because it provides a single drug to perform multiple functions in cancer treatment. The drug also shows promise for treating similar cancers in pets. “It is incredibly rewarding and exciting to potentially provide new options for people and for animals dealing with aggressive tumors,” Dr. Figueiredo said.

Dr. Figueiredo worked with her former graduate student, Sam Umbaugh, to develop this drug. She is currently collaborating with Dr. Herman Sintim, Purdue’s Drug Discovery Professor of Chemistry, to create different versions of the drug that are more effective against various types of cancers.  Click here to read a complete news release about the research.

Writer(s): Chris Adam, cladam@prf.org; Kevin Doerr | pvmnews@purdue.edu

Recent Stories

“Paws Up” – brought to you by the PVM Wellness Committee

This week, we are proud to recognize Lorraine Fox, who is a business assistant with the Veterinary Medicine Procurement Center.

PVM Interview Days Move College Closer to Admitting the DVM Class of 2030

After a total of three afternoons dedicated to conducting in-person interviews with 226 prospective veterinary students, the Purdue University College of Veterinary Medicine is close to completing the process of admitting 84 members of the incoming first-year DVM class – the Class of 2030.  The students invited for the interview days were selected from a total pool of 1,930 applicants from across the country as well as countries abroad.

Experts to Gather at Purdue for Conference Addressing the Public Health Threat of Antimicrobial Resistance

The ongoing challenges posed by multi-drug resistant infections will be the focus of a multidisciplinary conference taking place in three weeks at Purdue University.  The Fourth Annual Conference on Antimicrobial Resistance is set for February 25–26, 2026 at Purdue’s Stewart Center in West Lafayette. Registration is still open for the event, which will bring together scientists and scholars from human and veterinary medicine, public health, research, and industry to address the determinants, dynamics and deterrence of drug resistance.

PVM’s Upcoming Coppoc One Health Lecture to Focus on Dogs as Sentinels of Environmental Exposure

The Purdue University College of Veterinary Medicine brings a leading One Health scholar to campus each year to address vital health issues from a One Health perspective as part of the Coppoc One Health Lecture series.  This year’s presentation, scheduled for February 26 in Lynn Hall Room 2026, is on the engaging topic, “One Health at Home: Dogs as Sentinels of Environmental Exposure.” The speaker will be Audrey Ruple, DVM, MS, PhD, DACVPM, MRCVS, the Dorothy A. and Richard G. Metcalf Professor of Veterinary Medical Informatics at the Virginia-Maryland College of Veterinary Medicine at Virginia Tech.

“Paws Up” – brought to you by the PVM Wellness Committee

Today we are happy to acknowledge our Student Success Center Team.

One Health: A ‘digital twin’ model for predicting cancer outcomes

The striking similarities between invasive bladder cancer in dogs and humans have fueled research advances for more than three decades. Most of that work has looked at separate aspects of the disease — risk factors, early detection, symptoms, treatment and gene expression. But a new project at Purdue University that combines many types of available data in a “digital twin” model of bladder cancer may prove powerful enough to predict patient outcomes, starting with the probability of metastasis.

Purdue Professor Emeritus Bill Blevins Wins Lifetime Achievement Award at ACVR Annual Meeting

The American College of Veterinary Radiology (ACVR) gave its esteemed Lifetime Achievement Award for 2024 to Purdue Professor Emeritus Bill Blevins, who is well known to countless Purdue Veterinary Medicine alumni for the expertise he taught them about all things Diagnostic Imaging during his long Purdue career.